COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for ...

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported first-quarter earnings of $4.09 billion. The Bagsvaerd, Denmark-based company said it had profit of 92 ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

Novo Nordisk (NVO) is not a stock that is constantly staring at me from my screen, hoping I will get its attention. I like the Dow 30 and maybe another 20 stocks. I will consider just about ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

This came as Novo Nordisk India sought approval for Semaglutide tablets of 1.5 mg, 4 mg, and 9 mg of a new formulation based on the BE studies conducted in the USA and Canada. In light of earlier SEC ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...